Record 054 · Therapeutics · 2022
50%22.54.X
NewLimit
NewLimit
“Coinbase money on epigenetic reprogramming — restore cell identity, not just youth genes.”
NewLimit (Collison, Armstrong) treats reprogramming as an epigenetic software problem. Quiet, well-funded, discovery-first.
A 2020s therapeutics bet with consumer-tech LPs.
Series B+. Filed from the Top Tier Impact landscape.
- Epigenetic restoration
- Well-funded discovery
Reprogram the program.
